ArticleJournal of cannabis research2025
Trends in urine screening positive for cannabis of emergency department admissions in Israel 2016-2024.
Article in Journal of cannabis research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAlthough recreational cannabis is not yet legalized in Israel, the increase in cannabis prescriptions may lead to an increase in its availability and abuse.
aimsTo evaluate temporal changes in the prevalence of cannabis-positive urine toxicology tests among individuals admitted to the emergency department (ED) in a large tertiary medical center in Israel.
methodsBetween January/2016 and June/2024, all ED-admitted individuals who had urine toxicology tests (n = 20,022) were included.
resultsScreening with urine toxicology increased from 0.7% in 2016 to 1.3% in 2024 (p < 0.001). Of all screened patients, 16.8% (N = 3361) were cannabis-positive, rising from 15.4% (n = 112) in January-June/2016 to 17.6% (n = 246) in January-June/2024 (p < 0.001), with an increasing trend (p = 0.003) among the aged 25-64y group (n = 11901) from 16.6% in January-June/2016 to 22.4% in January-June/2024, and the highest proportion in < 25y age group (n = 2935, 23.8%). Logistic regression showed that later years (OR = 1.03, 95%CI 1.01–1.05), male sex (OR = 1.5, 95%CI 1.4–1.6), younger age (compared with aged ≥ 65, aged < 25, (OR = 4.1, 95%CI 3. 5-4.8), aged 25–64 (OR = 3.3, 95% CI 2.9–3.8)), Israeli-born (OR = 1.3, 95% CI 1.2–1.4), screening positive for opioid(OR = 1.4, 95%CI 1.2–1.5), MDMA (OR = 1.8, 95%CI 1.5–2.2), cocaine (OR = 1.3, 95%CI 1.2–1.5) methamphetamine (OR = 1.4, 95%CI 1.1–1.7) and not being hospitalized (OR = 1.4, 95%CI 1.3–1.5).
conclusionsThe exponential increase in cannabis prescriptions was not reflected in the modest increase in the proportion of cannabis-positive urine toxicology samples, that characterized the 25–64 age group. However, results may be biased, as toxicology screens were based on clinical suspicion without standardized ordering criteria, and diagnostic information regarding the ED visit was absent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.